
## Jing-Quan Wang

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9255159/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Paclitaxel and chemoresistance. , 2022, , 251-267.		1
2	PBK/TOPK inhibitor OTS964 resistance is mediated by ABCB1-dependent transport function in cancer: in vitro and in vivo study. Molecular Cancer, 2022, 21, 40.	7.9	5
3	Overexpression of ABCB1 Associated With the Resistance to the KRAS-G12C Specific Inhibitor ARS-1620 in Cancer Cells. Frontiers in Pharmacology, 2022, 13, 843829.	1.6	5
4	MET inhibitor tepotinib antagonizes multidrug resistance mediated by ABCG2 transporter: InÂvitro and inÂvivo study. Acta Pharmaceutica Sinica B, 2022, 12, 2609-2618.	5.7	7
5	Therapeutic implication of carbon monoxide in drug resistant cancers. Biochemical Pharmacology, 2022, 201, 115061.	2.0	4
6	Repurposing FDA-approved drugs for SARS-CoV-2 through an ELISA-based screening for the inhibition of RBD/ACE2 interaction. Protein and Cell, 2021, 12, 586-591.	4.8	18
7	Multidrug resistance proteins (MRPs): Structure, function and the overcoming of cancer multidrug resistance. Drug Resistance Updates, 2021, 54, 100743.	6.5	107
8	OTS964, a TOPK Inhibitor, Is Susceptible to ABCG2-Mediated Drug Resistance. Frontiers in Pharmacology, 2021, 12, 620874.	1.6	8
9	The Novel Benzamide Derivative, VKNG-2, Restores the Efficacy of Chemotherapeutic Drugs in Colon Cancer Cell Lines by Inhibiting the ABCG2 Transporter. International Journal of Molecular Sciences, 2021, 22, 2463.	1.8	10
10	Overexpression of ABCC1 Confers Drug Resistance to Betulin. Frontiers in Oncology, 2021, 11, 640656.	1.3	11
11	Insights on the structure–function relationship of human multidrug resistance protein 7 (MRP7/ABCC10) from molecular dynamics simulations and docking studies. MedComm, 2021, 2, 221-235.	3.1	7
12	Overexpression of human ATP-binding cassette transporter ABCG2 contributes to reducing the cytotoxicity of GSK1070916 in cancer cells. Biomedicine and Pharmacotherapy, 2021, 136, 111223.	2.5	12
13	Construction and Validation of a Nomogram for Predicting Progression- Free Survival in Patients with Early-Stage Testicular Germ Cell Tumor. Recent Patents on Anti-Cancer Drug Discovery, 2021, 16, 44-53.	0.8	Ο
14	Natural Product as Substrates of ABC Transporters: A Review. Recent Patents on Anti-Cancer Drug Discovery, 2021, 16, 222-238.	0.8	9
15	The role of androgen therapy in prostate cancer: from testosterone replacement therapy to bipolar androgen therapy. Drug Discovery Today, 2021, 26, 1293-1301.	3.2	11
16	Features of Cytokine Storm Identified by Distinguishing Clinical Manifestations in COVID-19. Frontiers in Public Health, 2021, 9, 671788.	1.3	31
17	Gold nanoparticles: synthesis, physiochemical properties and therapeutic applications in cancer. Drug Discovery Today, 2021, 26, 1284-1292.	3.2	65
18	Overexpression of ABCG2 Confers Resistance to MLN7243, a Ubiquitin-Activating Enzyme (UAE) Inhibitor. Frontiers in Cell and Developmental Biology, 2021, 9, 697927.	1.8	8

JING-QUAN WANG

#	Article	IF	CITATIONS
19	Enhancement of anticancer drug sensitivity in multidrug resistance cells overexpressing ATP-binding cassette (ABC) transporter ABCC10 by CP55, a synthetic derivative of 5-cyano-6-phenylpyrimidin. Experimental Cell Research, 2021, 405, 112728.	1.2	8
20	ATPâ€binding cassette (ABC) transporters in cancer: A review of recent updates. Journal of Evidence-Based Medicine, 2021, 14, 232-256.	0.7	57
21	VKNG-1 Antagonizes ABCG2-Mediated Multidrug Resistance via p-AKT and Bcl-2 Pathway in Colon Cancer: In Vitro and In Vivo Study. Cancers, 2021, 13, 4675.	1.7	4
22	Establishment and Characterization of a Novel Multidrug Resistant Human Ovarian Cancer Cell Line With Heterogenous MRP7 Overexpression. Frontiers in Oncology, 2021, 11, 731260.	1.3	6
23	The Spleen Tyrosine Kinase Inhibitor, Entospletinib (GS-9973) Restores Chemosensitivity in Lung Cancer Cells by Modulating ABCG2-mediated Multidrug Resistance. International Journal of Biological Sciences, 2021, 17, 2652-2665.	2.6	4
24	Antimicrobial Peptide Reverses ABCB1-Mediated Chemotherapeutic Drug Resistance. Frontiers in Pharmacology, 2020, 11, 1208.	1.6	23
25	NVP-CGM097, an HDM2 Inhibitor, Antagonizes ATP-Binding Cassette Subfamily B Member 1-Mediated Drug Resistance. Frontiers in Oncology, 2020, 10, 1219.	1.3	11
26	The Multidrug Resistance-Reversing Activity of a Novel Antimicrobial Peptide. Cancers, 2020, 12, 1963.	1.7	21
27	Bruton's Tyrosine Kinase (BTK) Inhibitor RN486 Overcomes ABCB1-Mediated Multidrug Resistance in Cancer Cells. Frontiers in Cell and Developmental Biology, 2020, 8, 865.	1.8	13
28	Reversal of Cancer Multidrug Resistance (MDR) Mediated by ATP-Binding Cassette Transporter G2 (ABCG2) by AZ-628, a RAF Kinase Inhibitor. Frontiers in Cell and Developmental Biology, 2020, 8, 601400.	1.8	18
29	Establishment and Characterization of a Topotecan Resistant Non-small Cell Lung Cancer NCI-H460/TPT10 Cell Line. Frontiers in Cell and Developmental Biology, 2020, 8, 607275.	1.8	9
30	Poziotinib Inhibits the Efflux Activity of the ABCB1 and ABCG2 Transporters and the Expression of the ABCG2 Transporter Protein in Multidrug Resistant Colon Cancer Cells. Cancers, 2020, 12, 3249.	1.7	19
31	M3814, a DNA-PK Inhibitor, Modulates ABCG2-Mediated Multidrug Resistance in Lung Cancer Cells. Frontiers in Oncology, 2020, 10, 674.	1.3	18
32	Sitravatinib, a Tyrosine Kinase Inhibitor, Inhibits the Transport Function of ABCG2 and Restores Sensitivity to Chemotherapy-Resistant Cancer Cells in vitro. Frontiers in Oncology, 2020, 10, 700.	1.3	25
33	Modulating the function of ABCB1: <i>in vitro</i> and <i>in vivo</i> characterization of sitravatinib, a tyrosine kinase inhibitor. Cancer Communications, 2020, 40, 285-300.	3.7	24
34	Reversal Effect of ALK Inhibitor NVP-TAE684 on ABCG2-Overexpressing Cancer Cells. Frontiers in Oncology, 2020, 10, 228.	1.3	15
35	Erdafitinib Antagonizes ABCB1-Mediated Multidrug Resistance in Cancer Cells. Frontiers in Oncology, 2020, 10, 955.	1.3	31
36	Biological evaluation of non-basic chalcone CYB-2 as a dual ABCG2/ABCB1 inhibitor. Biochemical Pharmacology, 2020, 175, 113848.	2.0	21

JING-QUAN WANG

#	Article	IF	CITATIONS
37	Venetoclax, a BCL-2 Inhibitor, Enhances the Efficacy of Chemotherapeutic Agents in Wild-Type ABCG2-Overexpression-Mediated MDR Cancer Cells. Cancers, 2020, 12, 466.	1.7	37
38	Overexpression of ABCB1 Transporter Confers Resistance to mTOR Inhibitor WYE-354 in Cancer Cells. International Journal of Molecular Sciences, 2020, 21, 1387.	1.8	25
39	Tivantinib, A c-Met Inhibitor in Clinical Trials, Is Susceptible to ABCG2-Mediated Drug Resistance. Cancers, 2020, 12, 186.	1.7	33
40	Elevated ABCB1 Expression Confers Acquired Resistance to Aurora Kinase Inhibitor GSK-1070916 in Cancer Cells. Frontiers in Pharmacology, 2020, 11, 615824.	1.6	14
41	Dual TTK/CLK2 inhibitor, CCâ€671, selectively antagonizes ABCG2â€mediated multidrug resistance in lung cancer cells. Cancer Science, 2020, 111, 2872-2882.	1.7	24
42	Abstract 2983: A synthetic derivative of 1,2,3-triazole-pyrimidine hybrid reverses multidrug resistance mediated by MRP7. , 2020, , .		2
43	Abstract 3006: Anticancer and multidrug resistance-reversing activities of novel antimicrobial peptides. , 2020, , .		1
44	Abstract 3010: VKNG 1 reverses multidrug resistance by inhibiting ABCG2 mediated drug transport in vitro and in vivo. , 2020, , .		1
45	Midostaurin Reverses ABCB1-Mediated Multidrug Resistance, an in vitro Study. Frontiers in Oncology, 2019, 9, 514.	1.3	29
46	Chk1 Inhibitor MK-8776 Restores the Sensitivity of Chemotherapeutics in P-glycoprotein Overexpressing Cancer Cells. International Journal of Molecular Sciences, 2019, 20, 4095.	1.8	19
47	Derivative of 5-cyano-6-phenylpyrimidin antagonizes ABCB1- and ABCG2-mediated multidrug resistance. European Journal of Pharmacology, 2019, 863, 172611.	1.7	22
48	Benzoyl indoles with metabolic stability as reversal agents for ABCG2-mediated multidrug resistance. European Journal of Medicinal Chemistry, 2019, 179, 849-862.	2.6	28
49	Tepotinib reverses ABCB1-mediated multidrug resistance in cancer cells. Biochemical Pharmacology, 2019, 166, 120-127.	2.0	52
50	Gaseous signaling molecules and their application in resistant cancer treatment: from invisible to visible. Future Medicinal Chemistry, 2019, 11, 323-336.	1.1	31
51	Tetrandrine Interaction with ABCB1 Reverses Multidrug Resistance in Cancer Cells Through Competition with Anti-Cancer Drugs Followed by Downregulation of ABCB1 Expression. Molecules, 2019, 24, 4383.	1.7	46
52	Selonsertib (GS-4997), an ASK1 inhibitor, antagonizes multidrug resistance in ABCB1- and ABCG2-overexpressing cancer cells. Cancer Letters, 2019, 440-441, 82-93.	3.2	83
53	Abstract 3796: Selonsertib, an ASK1 inhibitor, antagonizes ABCB1- and ABCG2-mediated chemotherapeutic drug resistance. Cancer Research, 2019, 79, 3796-3796.	0.4	1
54	Bolted Shear Connection of FRP-Concrete Hybrid Beams. Journal of Composites for Construction, 2018, 22, .	1.7	31

JING-QUAN WANG

#	Article	IF	CITATIONS
55	FRP stay-in-place form and shear key connection for FRP-concrete hybrid beams/decks. Composite Structures, 2018, 192, 489-499.	3.1	40
56	VS-4718 Antagonizes Multidrug Resistance in ABCB1- and ABCG2-Overexpressing Cancer Cells by Inhibiting the Efflux Function of ABC Transporters. Frontiers in Pharmacology, 2018, 9, 1236.	1.6	41
57	Modulating ROS to overcome multidrug resistance in cancer. Drug Resistance Updates, 2018, 41, 1-25.	6.5	420
58	Olmutinib (BI1482694/HM61713), a Novel Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, Reverses ABCG2-Mediated Multidrug Resistance in Cancer Cells. Frontiers in Pharmacology, 2018, 9, 1097.	1.6	47
59	Ulixertinib (BVD-523) antagonizes ABCB1- and ABCG2-mediated chemotherapeutic drug resistance. Biochemical Pharmacology, 2018, 158, 274-285.	2.0	47
60	Discovery of 5-Cyano-6-phenylpyrimidin Derivatives Containing an Acylurea Moiety as Orally Bioavailable Reversal Agents against P-Clycoprotein-Mediated Mutidrug Resistance. Journal of Medicinal Chemistry, 2018, 61, 5988-6001.	2.9	53
61	VSV-G Viral Envelope Glycoprotein Prepared from Pichia pastoris Enhances Transfection of DNA into Animal Cells. Journal of Microbiology and Biotechnology, 2017, 27, 1098-1105.	0.9	3
62	Dynamic characteristics analysis of partial-interaction composite continuous beams. Steel and Composite Structures, 2016, 21, 195-216.	1.3	13